GlassScriptPhysician profile
Wendy W Lee
NPI 1306979620
$615,779.83
in general payments reported to CMS, 2019-2025
32 companies · $31K in 2025
The $31K reported for 2025 was more than what 97% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178K · 2020: $48K · 2021: $112K · 2022: $153K · 2023: $51K · 2024: $44K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $73K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Travel and Lodging: $16K · Food and Beverage: $8,283 · Honoraria: $7,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $72,907.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,150.00 |
| Travel and Lodging | $16,242.84 |
| Food and Beverage | $8,282.77 |
| Honoraria | $7,870.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $266,461.87 | 2019-2022 | |
| Galderma Laboratories, L.P. | $130,018.35 | 2019-2025 | Dysport |
| Mallinckrodt Enterprises LLC | $74,948.36 | 2019 | |
| Abbvie INC. | $26,322.64 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $23,639.76 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $20,154.90 | 2019-2023 | Tepezza |
| Argenx US, INC. | $20,123.89 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $13,520.97 | 2024-2025 | Tepezza |
| Solta Medical, A Division of Bausch Health US, LLC | $12,180.00 | 2019-2021 | |
| Osmotica Pharmaceutical Corp. | $9,248.93 | 2019-2020 | |
| Oyster Point Pharma, INC. | $5,855.11 | 2023-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $5,328.48 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $4,557.20 | 2022-2025 | Miebo |
| Sun Pharmaceutical Industries INC. | $847.64 | 2022-2025 | Cequa, Xelpros, Bromsite |
| Revance Therapeutics, INC. | $654.86 | 2024-2025 | Daxxify |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $604.43 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $251.60 | 2023-2024 | Iolmaster 700 |
| Merz North America, INC. | $193.22 | 2019-2023 | Xeomin |
| Kala Pharmaceuticals, INC. | $138.94 | 2022 | |
| Alcon Vision LLC | $132.75 | 2022 | |
| Astellas Pharma US INC | $108.38 | 2023 | |
| Novartis Pharmaceuticals Corporation | $99.42 | 2020 | |
| Endo Pharmaceuticals INC. | $93.39 | 2019 | |
| Sight Sciences, INC. | $66.70 | 2020 | |
| Biotissue Holdings INC. | $49.77 | 2023 | |
| Ethicon US, LLC | $42.96 | 2025 | Vistaseal |
| Eyevance Pharmaceuticals LLC | $32.39 | 2019 | |
| Eyepoint US, INC. | $30.34 | 2019 | |
| Caris Mpi, INC. | $23.81 | 2025 | Mi Cancer Seek |
| Medtronic USA, INC. | $18.58 | 2020 | |
| Katalyst Surgical, LLC | $15.19 | 2023 | |
| Poriferous LLC | $15.00 | 2023 | Su-Por Surgical Implant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.